Cipla

As regulatory noise grows louder in the United States, Indian pharmaceutical giant Cipla Ltd. has sought to reassure investors and the broader healthcare market that the latest U.S. executive order aimed at reducing drug prices will not materially affect the generic drug industry. Managing Director and Global CEO Umang Vohra emphasized that the directive, while aggressive in rhetoric, targets branded drug manufacturers, not generic producers.

Cipla, one of India’s leading pharmaceutical companies, has announced a 30% increase in its consolidated net profit for the fourth quarter of FY25, reaching Rs 1,222 crore. This performance follows a similar upward trajectory for the full fiscal year, with the company reporting a 28% year-over-year growth in net profit. Total revenue for Q4 rose to Rs 6,730 crore, and the company also declared a final dividend of Rs 16 per share.